A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor Tuvusertib (M1774)

This study is testing two new targeted medications to see how they work together to stop the growth of advanced solid tumors. By blocking specific proteins that cancer cells need to repair themselves and grow, researchers hope to find a more effective way to treat cancers that haven't responded to standard therapies.

This trial is for adults 18 and older who have a solid tumor that has spread or cannot be removed by surgery and is no longer responding to standard treatments. Participants must have specific genetic markers in their tumor and generally feel well enough to participate.

You will receive two experimental drugs while being closely monitored by a medical team to ensure safety. The study involves regular check-ups, which include blood tests, tissue samples, and detailed imaging scans like CT or MRI to track how your cancer responds to the treatment.

The study is currently recruiting participants at clinical sites in Bethesda, Maryland, and Boston, Massachusetts. It is an active trial seeking patients who meet the specific medical criteria.